MedPath

Eyenuk, Inc.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

4

Active:0
Completed:4

Trial Phases

0 Phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Assessment of EyeArt Performance With Retinal Cameras

Completed
Conditions
Diabetic Retinopathy
Interventions
Procedure: Retinal imaging
Drug: Mydriatic Agent
First Posted Date
2021-07-30
Last Posted Date
2022-11-09
Lead Sponsor
Eyenuk, Inc.
Target Recruit Count
246
Registration Number
NCT04984200
Locations
🇺🇸

Rocky Mountain Diabetes Center, Idaho Falls, Idaho, United States

Assessment of EyeArt Performance With Retinal Imaging Devices

Completed
Conditions
Diabetic Retinopathy
First Posted Date
2020-03-10
Last Posted Date
2021-07-08
Lead Sponsor
Eyenuk, Inc.
Target Recruit Count
62
Registration Number
NCT04302012
Locations
🇺🇸

Lundquist Institute, Los Angeles, California, United States

Assessment of EyeArt as an Automated Diabetic Retinopathy Screening Tool

Completed
Conditions
Diabetic Eye Problems
Diabetic Retinopathy
Diabetic Macular Edema
First Posted Date
2017-04-13
Last Posted Date
2018-07-30
Lead Sponsor
Eyenuk, Inc.
Target Recruit Count
942
Registration Number
NCT03112005
Locations
🇺🇸

Los Angeles Biomedical Research Institute, Los Angeles, California, United States

Pilot Assessment of EyeArt as an Automated Diabetic Retinopathy Screening Tool

Completed
Conditions
Diabetic Retinopathy
First Posted Date
2017-03-13
Last Posted Date
2018-07-30
Lead Sponsor
Eyenuk, Inc.
Target Recruit Count
52
Registration Number
NCT03078231
Locations
🇺🇸

LAC+USC Medical Center, Los Angeles, California, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.